OPTEY (Ceryvyn Therapeutics) Total Liabilities: $257.87 Mil (As of Jun. 2025)


What is Ceryvyn Therapeutics Total Liabilities?

Ceryvyn Therapeutics OPTEY Total Liabilities is $257.87 Mil as of Jun. 2025. The stock has 3 warning signs investors should review.

Ceryvyn Therapeutics's Total Liabilities for the quarter that ended in Jun. 2025 was $257.87 Mil.

Ceryvyn Therapeutics's quarterly Total Liabilities increased from Jun. 2024 ($264.60 Mil) to Dec. 2024 ($314.48 Mil) but then declined from Dec. 2024 ($314.48 Mil) to Jun. 2025 ($257.87 Mil).

Ceryvyn Therapeutics's annual Total Liabilities increased from Jun. 2023 ($104.49 Mil) to Jun. 2024 ($264.60 Mil) but then declined from Jun. 2024 ($264.60 Mil) to Jun. 2025 ($257.87 Mil).

Ceryvyn Therapeutics Total Liabilities Historical Data

* Premium members only.

The historical data trend for Ceryvyn Therapeutics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ceryvyn Therapeutics Total Liabilities Chart

Ceryvyn Therapeutics Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.12 12.07 104.49 264.60 257.87

Ceryvyn Therapeutics Semi-Annual Data
Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 104.49 213.41 264.60 314.48 257.87

Ceryvyn Therapeutics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Ceryvyn Therapeutics's Total Liabilities for the fiscal year that ended in Jun. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=257.868+(0+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=257.87

Total Liabilities=Total Assets (A: Jun. 2025 )-Total Equity (A: Jun. 2025 )
=56.799--201.069
=257.87

Ceryvyn Therapeutics's Total Liabilities for the quarter that ended in Jun. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=257.868+(0+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=257.87

Total Liabilities=Total Assets (Q: Jun. 2025 )-Total Equity (Q: Jun. 2025 )
=56.799--201.069
=257.87

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $257.87 Mil mean?
Ceryvyn Therapeutics (OPTEY) has a Total Liabilities of $257.87 Mil as of Jun. 2025. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Ceryvyn Therapeutics and its competitors.
Is Ceryvyn Therapeutics' Total Liabilities too high?
Ceryvyn Therapeutics' current Total Liabilities is $257.87 Mil.
How does Ceryvyn Therapeutics' Total Liabilities compare to VRTX and REGN?
Ceryvyn Therapeutics' Total Liabilities of $257.87 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Ceryvyn Therapeutics and its competitors. Ceryvyn Therapeutics's current Total Liabilities is $257.87 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ceryvyn Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Ceryvyn Therapeutics (OPTEY) is currently considered Possible Value Trap. The stock's GF Value™ is $1.88, compared to a current price of $0.03 — trading 98.6% below its estimated fair value. The current Total Liabilities is $257.87 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Ceryvyn Therapeutics (OPTEY), the current Total Liabilities is $257.87 Mil as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Ceryvyn Therapeutics Business Description

Address C/ Prime Company Compliance, 505 Little Collins Street, Level 9, Melbourne, VIC, AUS, 3000
Opthea Ltd is engaged in researching and developing novel therapeutic products that target Vascular Endothelial Growth Factors (VEGF) C, D, and R3. The Group operates in one industry and two geographical areas, namely biotechnology and healthcare, with operations in Australia and the United States. The company focuses on developing biological therapeutics for eye diseases and is currently developing a novel biologic therapy, OPT-302, for the treatment of eye conditions. Its products are based on an intellectual property portfolio covering VEGF-C, VEGF-D, and VEGF Receptor-3 targets, aimed at treating diseases associated with blood and lymphatic vessel growth and vascular leakage.